Neurocrine Biosciences (NBIX) Equity Income (2019 - 2026)

Neurocrine Biosciences has reported Equity Income for 8 years, with the latest figure at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Income rose 182.68% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $51.9 million (up 174.89% YoY), and the FY2025 full-year result was -$4.0 million, up 89.22% from the prior year.
• Equity Income for Q1 2026 stood at $25.3 million, up from $2.7 million in the prior quarter.
• The five-year high for Equity Income was $37.3 million in Q2 2023, with the low at -$40.1 million in Q3 2023.
• Historically, Equity Income has averaged $2.6 million across 5 years, with a median of $2.2 million in 2023.
• Annual changes were most pronounced in 2022 — Equity Income surged 2742.86% — and 2025, when it plunged 2012.5%.
• Neurocrine Biosciences' Equity Income stood at $7.2 million in 2022, then soared by 302.78% to $29.0 million in 2023, then plunged by 106.55% to -$1.9 million in 2024, then soared by 242.11% to $2.7 million in 2025, then surged by 837.04% to $25.3 million in 2026.
• The last three Equity Income figures came in at $25.3 million (Q1 2026), $2.7 million (Q4 2025), and $30.6 million (Q3 2025), per Business Quant data.